BioSig Technologies, a medical technology company commercializing a proprietary biomedical signal processing platform, has filed for consideration with the FDA under the Coronavirus Treatment Acceleration Program (CTAP) for Vicromax, an orally administered drug that could be delivered to patients during all stages of Covid-19 – early-stage right when the patient starts to feel symptoms, mid-stage, or even late-stage while in the ICU. Earlier in the week, the company announced that the Mayo...